Chemical blocking of zinc ions in CNS increases neuronal damage following traumatic brain injury (TBI) in mice.
BACKGROUND
Traumatic brain injury (TBI) is one of the leading causes of disability and death among young people. Although much is already known about secondary brain damage the full range of brain tissue responses to TBI remains to be elucidated. A population of neurons located in cerebral areas associated with higher cognitive functions harbours a vesicular zinc pool co-localized with glutamate. This zinc enriched pool of synaptic vesicles has been hypothesized to take part in the injurious signalling cascade that follows pathological conditions such as seizures, ischemia and traumatic brain injury. Pathological release of excess zinc ions from pre-synaptic vesicles has been suggested to mediate cell damage/death to postsynaptic neurons.


RESULTS
In order to substantiate the influence of vesicular zinc ions on TBI, we designed a study in which damage and zinc movements were analysed in several different ways. Twenty-four hours after TBI ZnT3-KO mice (mice without vesicular zinc) were compared to littermate Wild Type (WT) mice (mice with vesicular zinc) with regard to histopathology. Furthermore, in order to evaluate a possible neuro-protective dimension of chemical blocking of vesicular zinc, we treated lesioned mice with either DEDTC or selenite. Our study revealed that chemical blocking of vesicular zinc ions, either by chelation with DEDTC or accumulation in zinc-selenium nanocrystals, worsened the effects on the aftermath of TBI in the WT mice by increasing the number of necrotic and apoptotic cells within the first 24 hours after TBI, when compared to those of chemically untreated WT mice.


CONCLUSIONS
ZnT3-KO mice revealed more damage after TBI compared to WT controls. Following treatment with DEDTC or selenium an increase in the number of both dead and apoptotic cells were seen in the controls within the first 24 hours after TBI while the degree of damage in the ZnT3-KO mice remained largely unchanged. Further analyses revealed that the damage development in the two mouse strains was almost identical after either zinc chelation or zinc complexion therapy.
Doering
Peter
P
Institute of Anatomy, Neurobiology, University of Aarhus, Aarhus, Denmark. pdj@neuro.au.dk
Stoltenberg
Meredin
M
Penkowa
Milena
M
Rungby
Jørgen
J
Larsen
Agnete
A
Danscher
Gorm
G
D000818:Animals; D001930:Brain Injuries / Q000378:metabolism* / Q000473:pathology; D016923:Cell Death / Q000187:drug effects; D002490:Central Nervous System / Q000378:metabolism / Q000473:pathology*; D002614:Chelating Agents / Q000494:pharmacology; D004050:Ditiocarb / Q000031:analogs & derivatives / Q000494:pharmacology; D018698:Glutamic Acid; D051379:Mice; D018345:Mice, Knockout; D009474:Neurons / Q000187:drug effects / Q000473:pathology*; D018038:Sodium Selenite / Q000494:pharmacology; D015032:Zinc / Q000172:deficiency* / Q000378:metabolism
D002614:Chelating Agents; D018698:Glutamic Acid; D004050:Ditiocarb; D018038:Sodium Selenite; C039353:dihydroxyethyldithiocarbamate; D015032:Zinc
J Physiol. 2005 Aug 1;566(Pt 3):821-37
15919712
J Alzheimers Dis. 2005 Nov;8(2):155-60; discussion 209-15
16308484
Histochem Cell Biol. 2008 Oct;130(4):681-92
18542984
J Pharmacol Sci. 2006 Feb;100(2):142-8
16474205
J Chem Neuroanat. 1996 Aug;11(2):99-111
8877598
Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12676-81
9356509
Nutr Neurosci. 2002 Oct;5(5):345-52
12385597
Neuroscience. 2007 Dec 5;150(2):357-69
17949919
Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1716-21
9990090
Neuroscience. 1990;38(3):843-54
2176723
Brain Res Brain Res Rev. 2000 Dec;34(3):137-48
11113504
J Neurosci. 2000 Jun 1;20(11):RC79
10807937
Brain Res. 1975 Mar 7;85(3):522-6
163124
Neuroscience. 2008 Dec 2;157(3):697-707
18840509
J Nutr. 2000 May;130(5S Suppl):1471S-83S
10801962
Epilepsy Res. 2000 Apr;39(2):153-69
10759303
Neuroscience. 2002;115(3):871-8
12435425
Nature. 1984 Apr 19-25;308(5961):734-6
6717566
Neuroscience. 2009 Jan 12;158(1):126-36
18353558
J Neurosci Methods. 2004 Oct 15;139(1):79-89
15351524
J Comp Neurol. 2004 Nov 8;479(2):156-67
15452827
Brain Res. 2001 Dec 7;921(1-2):165-72
11720723
Neuroscience. 1992;48(2):325-52
1376449
J Cereb Blood Flow Metab. 2006 Feb;26(2):161-9
15988476
Brain Res. 1989 Feb 20;480(1-2):317-21
2713657
Neuroscience. 2007 Nov 30;150(1):93-103
17996379
Brain Res. 1985 Jun 24;337(1):91-8
2408711
Trends Neurosci. 2000 Aug;23(8):365-71
10906800
Neuroscience. 2004;125(4):867-77
15120848
Neuroscience. 2001;105(4):941-7
11530232
Exp Brain Res. 1973 Mar 19;16(5):521-32
4121158
Epilepsia. 2006 May;47(5):887-99
16686654
Prog Histochem Cytochem. 2006;41(2):57-139
16949439
Mol Cell Neurosci. 2002 Oct;21(2):189-204
12401442
Neurosci Lett. 2002 Mar 15;321(1-2):37-40
11872251
Science. 1996 May 17;272(5264):1013-6
8638123
Eur J Neurosci. 2000 Jul;12(7):2311-22
10947810
Neurosci Lett. 2008 Aug 1;440(2):155-9
18556117
Neurosci Lett. 1999 Dec 24;277(2):75-8
10624813
Brain Res. 2000 Jan 10;852(2):268-73
10678752
J Neurochem. 2003 May;85(3):563-70
12694382
Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14934-9
8962159
Brain Res. 2001 Mar 23;895(1-2):25-32
11259756
Biometals. 2009 Feb;22(1):149-57
19130267
Synapse. 2009 Nov;63(11):1029-49
19623531
J Histochem Cytochem. 2008 Jan;56(1):3-6
17712179
Nature. 1984 Apr 19-25;308(5961):736-8
6717567
Brain Res. 1998 Nov 23;812(1-2):265-9
9813362
Exp Neurol. 2003 Nov;184(1):337-47
14637104
Biometals. 2001 Sep-Dec;14(3-4):343-51
11831464
Histochemistry. 1982;76(3):281-93
6186642
Brain Res. 2000 Aug 25;874(2):123-30
10960596
J Histochem Cytochem. 2005 Feb;53(2):141-53
15684327